This paper merely suggests that a drug used for treating schizophrenia can inhibit some aspects of the experiences that individuals have on psylocibin. The paper does not suggest long term damage and if it did, the study would have been terminated early and psylocibin would not be acceptable for continued research in Switzerland (where the study was conducted) or in the US.